cefixime has been researched along with Diarrhea in 15 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cefixime, a new third generation oral cephalosporin antibiotic, was evaluated for safety and efficacy in the treatment of 206 children with acute bacterial pharyngitis, cystitis or pneumonia." | 9.06 | Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients. ( Barone, JS; Clark, PA; Risser, WL; Simpkins, DL, 1987) |
| "Without cefixime, diarrhea was dose limiting at irinotecan 45 mg/m2/d." | 5.12 | Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. ( Billups, C; Crews, KR; Daw, NC; Dome, JS; Furman, WL; Gajjar, AJ; Houghton, PJ; Panetta, JC; Patrick, CC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Wu, J, 2006) |
| "Cefixime, a new third generation oral cephalosporin antibiotic, was evaluated for safety and efficacy in the treatment of 206 children with acute bacterial pharyngitis, cystitis or pneumonia." | 5.06 | Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients. ( Barone, JS; Clark, PA; Risser, WL; Simpkins, DL, 1987) |
| "The clinical and laboratory safety of cefixime based on analysis of data from 1575 adults (1118 treated daily and 457 treated twice a day) and 615 children (299 treated daily and 316 treated twice a day) in studies of urinary tract and lower and upper respiratory tract infections (including otitis media) is reviewed." | 5.06 | Safety profile of cefixime. ( Cartwright, K; Desjardins, RE; McCarthy, EF; Tally, FP, 1987) |
| "Gastrointestinal toxicity, such as late-onset diarrhea, is a significant concern in irinotecan hydrochloride (CPT-11)-containing regimens." | 3.83 | Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride. ( Fujita, D; Nakanishi, T; Saito, Y; Tamai, I, 2016) |
| "A clinical study of cefixime (CFIX), a new oral cephalosporin, was carried out to evaluate its therapeutic effectiveness on bacterial infections in children." | 3.67 | [Clinical studies on cefixime in pediatrics]. ( Endo, S; Hosoda, T; Masuda, M; Mimoto, H; Miyao, M; Tanaka, H; Yuasa, Y, 1986) |
| "Cefixime is a cephalosporin antibiotic that is more active against Proteus spp." | 1.28 | An improved selective medium for the isolation of Escherichia coli O157. ( Chapman, PA; Jewes, L; Siddons, CA; Zadik, PM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Novembre, E | 1 |
| Mori, F | 1 |
| Barni, S | 1 |
| Pucci, N | 1 |
| Rogawski, ET | 1 |
| Westreich, DJ | 1 |
| Becker-Dreps, S | 1 |
| Adair, LS | 1 |
| Sandler, RS | 1 |
| Sarkar, R | 1 |
| Kattula, D | 1 |
| Ward, HD | 1 |
| Meshnick, SR | 1 |
| Kang, G | 1 |
| Fujita, D | 1 |
| Saito, Y | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
| Furman, WL | 1 |
| Crews, KR | 1 |
| Billups, C | 1 |
| Wu, J | 1 |
| Gajjar, AJ | 1 |
| Daw, NC | 1 |
| Patrick, CC | 1 |
| Rodriguez-Galindo, C | 1 |
| Stewart, CF | 1 |
| Dome, JS | 1 |
| Panetta, JC | 1 |
| Houghton, PJ | 1 |
| Santana, VM | 1 |
| Gales, MA | 1 |
| Gales, BJ | 1 |
| Chachaty, E | 1 |
| Bourneix, C | 1 |
| Renard, S | 1 |
| Bonnay, M | 1 |
| Andremont, A | 1 |
| Chapman, PA | 2 |
| Siddons, CA | 2 |
| Hornitzky, MA | 1 |
| Bettelheim, KA | 1 |
| Djordjevic, SP | 1 |
| Bartlett, JG | 1 |
| Zadik, PM | 1 |
| Jewes, L | 1 |
| Piippo, T | 1 |
| Stefansson, S | 1 |
| Pitkäjärvi, T | 1 |
| Lundberg, C | 1 |
| Risser, WL | 1 |
| Barone, JS | 1 |
| Clark, PA | 1 |
| Simpkins, DL | 1 |
| Tally, FP | 1 |
| Desjardins, RE | 1 |
| McCarthy, EF | 1 |
| Cartwright, K | 1 |
| Hosoda, T | 1 |
| Masuda, M | 1 |
| Miyao, M | 1 |
| Mimoto, H | 1 |
| Endo, S | 1 |
| Yuasa, Y | 1 |
| Tanaka, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Multicenter Randomized Controlled Trial to Establish the Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) (JUPITER TRIAL)"[NCT05762302] | 1,316 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | |||
| Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea[NCT04491799] | 135 participants (Actual) | Observational | 2019-02-01 | Completed | |||
| Evaluation of the Impact of an Amoxicillin and Amoxicillin/Clavulanic Acid Resistant Probiotic on Key Clinical Outcomes in Children Treated With Amoxicillin or Amoxicillin/Clavulanic Acid[NCT05840588] | 300 participants (Anticipated) | Interventional | 2023-04-10 | Recruiting | |||
| Efficacy of the Application of Moxifloxacin and Cefixime in Reduction of Inflammatory Sequelae and Complications After Mandibular Third Molar Surgery[NCT05027893] | 157 participants (Actual) | Interventional | 2019-06-07 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cefixime and Diarrhea
| Article | Year |
|---|---|
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
Clinical practice. Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Cefixime; Clostridioides difficile; Colon; Diagnosis, Differential; Diarrhea; | 2002 |
4 trials available for cefixime and Diarrhea
| Article | Year |
|---|---|
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cefixime; | 2006 |
Double-blind comparison of cefixime and cefaclor in the treatment of acute otitis media in children.
Topics: Acute Disease; Anti-Bacterial Agents; Cefaclor; Cefixime; Cefotaxime; Child; Child, Preschool; Diarr | 1991 |
Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients.
Topics: Adolescent; Cefixime; Cefotaxime; Child; Child, Preschool; Clinical Trials as Topic; Cystitis; Diarr | 1987 |
Safety profile of cefixime.
Topics: Adult; Cefixime; Cefotaxime; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Admin | 1987 |
10 other studies available for cefixime and Diarrhea
| Article | Year |
|---|---|
Drug-induced enterocolitis syndrome (DIES).
Topics: Amoxicillin; Anti-Bacterial Agents; Cefixime; Child; Dairy Products; Diarrhea; Drug Eruptions; Drug | 2014 |
Antibiotic treatment of diarrhoea is associated with decreased time to the next diarrhoea episode among young children in Vellore, India.
Topics: Anti-Bacterial Agents; Cefixime; Child, Preschool; Diarrhea; Female; Humans; India; Infant; Infant, | 2015 |
Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bacteria; Bacterial Proteins; Camptothecin; Ce | 2016 |
Recognition of severe cefixime-induced diarrhea.
Topics: Anti-Infective Agents; Cefixime; Cefotaxime; Diarrhea; Female; Humans; Middle Aged | 1993 |
Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; Cefixime; Cefotaxim | 1993 |
A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from cases of bloody diarrhoea, non-bloody diarrhoea and asymptomatic contacts.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Toxins; Bacteriophage Typing; Cefixime; Cef | 1996 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-1998. A 70-year-old man with diarrhea, polyarthritis, and a history of Reiter's syndrome.
Topics: Aged; Arthritis; Arthritis, Reactive; Cefixime; Cefotaxime; Cephalosporins; Clostridioides difficile | 1998 |
The detection of Shiga toxin-producing Escherichia coli in diagnostic bovine faecal samples using vancomycin-cefixime-cefsulodin blood agar and PCR.
Topics: Adhesins, Bacterial; Animals; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacteriological | 2001 |
An improved selective medium for the isolation of Escherichia coli O157.
Topics: Anti-Infective Agents, Urinary; Bacterial Toxins; Cefixime; Cefotaxime; Culture Media; Diarrhea; Esc | 1991 |
[Clinical studies on cefixime in pediatrics].
Topics: Bacteria; Bacterial Infections; Cefixime; Cefotaxime; Chemical and Drug Induced Liver Injury; Child; | 1986 |